Loading the SOTA2 catalog…
InVision Medical Technology
Develops clinically-validated AI for echocardiography, streamlining interpretation, standardizing measurements, and surfacing undiagnosed disease. Founded and led by clinicians and computer scientists from Stanford and Cedars-Sinai. Backed by Y Combinator and strategic partners including Alexion, AstraZeneca Rare Disease, with live deployments through partners like HeartLab.
- Founded
- 2022
- Headquarters
- San Francisco
- Company size
- 1–10
- Products tracked
- 6
Products by InVision Medical Technology
Pricing for InVision Medical Technology
Contact sales
Contact InVision Medical Technology for current plans, volume pricing, and enterprise terms.
Trust profile
Security and compliance
SOC 2
ISO 9001
HIPAA
FDA 510(k) Clearance — Precision LVEF
FDA 510(k) Clearance — Precision Cardiac Amyloid
FDA Breakthrough Device Designation — Precision Cardiac Amyloid
FDA Breakthrough Device Designation — Precision Cirrhosis
FDA Total Product Lifecycle Advisory Program (TAP) — Precision Cardiac Amyloid
CPT Category III code 0932T (effective January 1, 2025) — Precision Cardiac Amyloid
DICOM Part 15 compliance — Automatic DICOM Deidentification
Session-only cookies (no persistent cookies)
Commercially reasonable physical, managerial, and technical safeguards
Security breach notification to affected users
Third-party processors required to use reasonable confidentiality measures and comply with Privacy Policy